Compounds useful as motilin agonists and method
    11.
    发明授权
    Compounds useful as motilin agonists and method 有权
    可用作胃动素激动剂和方法的化合物

    公开(公告)号:US07338954B2

    公开(公告)日:2008-03-04

    申请号:US10940241

    申请日:2004-09-14

    IPC分类号: A01N43/58 C07D237/00

    CPC分类号: C07D471/20 A61K31/503

    摘要: A method is provided for treating disorders of gastrointestinal motility which include the steps of administering to a patient in need of treatment of a compound having the structure or a pharmaceutically acceptable salt thereof, a prodrug ester thereof, and all stereoisomers thereof, wherein R1 is selected from alkyl, aryl, cycloalkyl, alkenyl, alkynyl, arylalkyl, heteroaryl, heteroarylalkyl or heterocycloalkyl; Z is selected from —CON(R4)R4a, —SO2N(R4)R4a, —CN, and R4 and R4a are the same or different and are independently selected from hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl or R4 and R4a can be joined together to form a heterocycle; R4b is selected from hydrogen, halogen, hydroxyl, CN, OCF3, CF3, CONH2, SONH2, SO2CH3, NHCOCH3 or NHCO2CH3; and Q is a substituted bicyclic heterocycle. New compounds for use in treating disorders of gastrointestinal motility are also provided.

    摘要翻译: 提供了一种用于治疗胃肠蠕动障碍的方法,其包括对需要治疗具有其结构的化合物或其药学上可接受的盐,其前药酯及其所有立体异构体的患者施用的步骤,其中R 3 Q是取代的双环杂环。 还提供了用于治疗胃肠蠕动障碍的新化合物。

    Heterocyclic inhibitors of microsomal triglyceride transfer protein and
method
    15.
    发明授权
    Heterocyclic inhibitors of microsomal triglyceride transfer protein and method 失效
    微粒体甘油三酯转运蛋白的杂环抑制剂及方法

    公开(公告)号:US5965577A

    公开(公告)日:1999-10-12

    申请号:US986854

    申请日:1997-12-08

    申请人: Joseph A. Tino

    发明人: Joseph A. Tino

    摘要: Novel compounds are provided which are inhibitors of MTP and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases, and have the structure ##STR1## including pharmaceutically acceptable salts thereof, or prodrug esters thereof,A is ##STR2## where Z is N or CH, or where Z is ##STR3## or CH.sub.2 when --- is a single bond; Q is (1)--O--;(2)--S--; or ##STR4## B is: ##STR5## and wherein L.sup.1, R, R.sup.1, R.sup.3, R.sup.3 ', R.sup.3a, R.sup.3b, R.sup.4, R.sup.4 ', R.sup.5, R.sup.5a, X, ##STR6## are as defined herein.

    摘要翻译: 提供了作为MTP抑制剂的新型化合物,因此可用于降低血清脂质和治疗动脉粥样硬化和相关疾病,并且具有包括其药学上可接受的盐或其前药酯的结构,A是Z是N或CH,或其中 当+ E时,Z为或CH2,ovs --- + EE为单键; Q是(1)-O-; (2)-S-; 或B是:并且其中L1,R,R1,R3,R3',R3a,R3b,R4,R4',R5,R5a,X如本文所定义。

    Substituted pyrazolylamides useful as glucokinase activators
    16.
    发明授权
    Substituted pyrazolylamides useful as glucokinase activators 有权
    用作葡糖激酶活化剂的取代的吡唑基酰胺

    公开(公告)号:US08614332B2

    公开(公告)日:2013-12-24

    申请号:US13397123

    申请日:2012-02-15

    IPC分类号: C07D231/00

    摘要: Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure is a heteroaryl ring; R4 is —(CH2)n—Z—(CH2)m—PO(OR7)(OR8), —(CH2)nZ—(CH2)m—PO(OR7)R9, —(CH2)n—Z—(CH2)m—OPO(OR7)R9, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10); R5 and R6 are independently selected from H, alkyl and halogen; Y is R7(CH2)s or is absent; and X, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

    摘要翻译: 提供了膦酸酯和次膦酸酯活化剂的化合物,因此可用于治疗糖尿病和相关疾病,并且其结构是杂芳基环; R4是 - (CH2)nZ-(CH2)m-PO(OR7)(OR8), - (CH2)nZ-(CH2)m-PO(OR7)R9, - (CH2)nZ-(CH2) (OR7)R9, - (CH2)nZ-(CH2)m-OPO(R9)(R10)或 - (CH2)nZ-(CH2)m-PO(R9)(R10) R5和R6独立地选自H,烷基和卤素; Y为R 7(CH 2)s或不存在; 并且X,n,Z,m,R 4,R 5,R 6,R 7和s如本文所定义; 或其药学上可接受的盐。 还提供了使用上述化合物治疗糖尿病和相关疾病的方法。

    Substituted pyrazolylamide compounds useful as glucokinase activators
    17.
    发明授权
    Substituted pyrazolylamide compounds useful as glucokinase activators 有权
    用作葡糖激酶活化剂的取代的吡唑基酰胺化合物

    公开(公告)号:US08153677B2

    公开(公告)日:2012-04-10

    申请号:US13012351

    申请日:2011-01-24

    IPC分类号: A61K31/415

    摘要: Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n—Z—(CH2)m—PO(OR7)(OR8), —(CH2)nZ—(CH2)m—OPO(OR7)R9, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10); R5 and R6 are independently selected from hydrogen, alkyl and halogen; Y is R7(CH2)s or is absent; and X, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

    摘要翻译: 提供了膦酸酯和次膦酸酯活化剂的化合物,因此可用于治疗糖尿病和相关疾病,并且其结构是杂芳基环; R4是 - (CH2)n-Z-(CH2)m-PO(OR7)(OR8), - (CH2)nZ-(CH2)m-OPO(OR7)R9, - (CH2)nZ-(CH2) -OPO(R9)(R10)或 - (CH2)nZ-(CH2)m-PO(R9)(R10); R5和R6独立地选自氢,烷基和卤素; Y为R 7(CH 2)s或不存在; 并且X,n,Z,m,R 4,R 5,R 6,R 7和s如本文所定义; 或其药学上可接受的盐。 还提供了使用上述化合物治疗糖尿病和相关疾病的方法。